Information  X 
Enter a valid email address

MavIncGroVCT4 (MAV4)

  Print      Mail a friend

Monday 19 November, 2018

MavIncGroVCT4

Director/PDMR Shareholding

RNS Number : 7781H
Maven Income & Growth VCT 4 PLC
19 November 2018
 

Maven Income and Growth VCT 4 PLC ("the Company")

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

William Robert Nixon

 

2

 

Reason for the notification

 

a)

 

Position/status

 

Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

Maven Income and Growth VCT 4 PLC

b)

 

LEI

 

213800WSH2TNL9NG5I06

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 10p each

 

 

MAV4

 

b)

 

Nature of the transaction

 

Additional Shares arising from Merger with Maven Income and Growth VCT 2 PLC

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

70.5621p

119,687

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

119,687 Ordinary shares of 10p each

 

70.5621p

e)

 

Date of the transaction

 

15 November 2018

f)

 

Place of the transaction

 

London

g)

Name of contact and telephone number for queries

 

David Russell, Maven Capital Partners UK LLP

Company Secretary (Tel: 0141 206 0107)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHEAFFNFDNPFFF

a d v e r t i s e m e n t